Delivering bioactive cyclic peptides that target Hsp90 as prodrugs
The most challenging issue facing peptide drug development is producing a molecule with optimal physical properties while maintaining target binding affinity. Masking peptides with protecting groups that can be removed inside the cell, produces a cell-permeable peptide, which theoretically can maint...
Main Authors: | Yuantao Huo, Laura K. Buckton, Jack L. Bennett, Eloise C. Smith, Frances L. Byrne, Kyle L. Hoehn, Marwa N. Rahimi, Shelli R. McAlpine |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2019-01-01
|
Series: | Journal of Enzyme Inhibition and Medicinal Chemistry |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/14756366.2019.1580276 |
Similar Items
-
Hsp90 Activity Is Necessary for the Maturation of Rabies Virus Polymerase
by: Iga Dalidowska, et al.
Published: (2022-06-01) -
The Distinct Assignments for Hsp90α and Hsp90β: More Than Skin Deep
by: Cheng Chang, et al.
Published: (2023-01-01) -
Design of Disruptors of the Hsp90–Cdc37 Interface
by: Ilda D’Annessa, et al.
Published: (2020-01-01) -
Regulation of Protein Transport Pathways by the Cytosolic Hsp90s
by: Anna G. Mankovich, et al.
Published: (2022-08-01) -
Recognition of tumor-targeting peptide P7 related to the expression level of Hsp90
by: KONG De-xin, HUANG Wei, YANG Nan, LIU Yan-yong
Published: (2021-07-01)